Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE3.6100
- TODAY'S CHANGE (%)-0.1900 (-5.0000%)
- Bid / Lots3.3500/ 1
- Ask / Lots3.7600/ 1
- Open / Previous Close3.8600 / 3.8000
- Day Range
- 52 Week Range
- Volume252,320
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KOD |
|---|---|---|
| 09:32 ET | 3979 | 3.9 |
| 09:34 ET | 195 | 3.8157 |
| 09:36 ET | 300 | 3.83 |
| 09:38 ET | 1000 | 3.82 |
| 09:39 ET | 400 | 3.8 |
| 09:41 ET | 100 | 3.78 |
| 09:43 ET | 100 | 3.79 |
| 09:48 ET | 100 | 3.785 |
| 09:50 ET | 200 | 3.795 |
| 09:54 ET | 200 | 3.785 |
| 09:56 ET | 100 | 3.79 |
| 09:57 ET | 940 | 3.795 |
| 09:59 ET | 300 | 3.8 |
| 10:01 ET | 2109 | 3.76 |
| 10:06 ET | 400 | 3.77 |
| 10:08 ET | 400 | 3.76 |
| 10:10 ET | 300 | 3.76 |
| 10:12 ET | 1300 | 3.7501 |
| 10:14 ET | 6174 | 3.75 |
| 10:15 ET | 150 | 3.75 |
| 10:17 ET | 200 | 3.74 |
| 10:21 ET | 1400 | 3.72 |
| 10:24 ET | 5700 | 3.715 |
| 10:26 ET | 26635 | 3.69 |
| 10:30 ET | 939 | 3.68 |
| 10:32 ET | 200 | 3.68 |
| 10:33 ET | 3803 | 3.69 |
| 10:35 ET | 1300 | 3.685 |
| 10:39 ET | 200 | 3.7 |
| 10:42 ET | 852 | 3.69 |
| 10:44 ET | 2000 | 3.6899 |
| 10:46 ET | 500 | 3.69 |
| 10:48 ET | 400 | 3.685 |
| 10:51 ET | 363 | 3.685 |
| 10:53 ET | 641 | 3.68 |
| 10:55 ET | 100 | 3.67 |
| 10:57 ET | 178 | 3.67 |
| 11:00 ET | 100 | 3.68 |
| 11:02 ET | 400 | 3.665 |
| 11:04 ET | 598 | 3.67 |
| 11:09 ET | 200 | 3.665 |
| 11:13 ET | 1100 | 3.67 |
| 11:20 ET | 300 | 3.675 |
| 11:22 ET | 10223 | 3.66 |
| 11:29 ET | 200 | 3.6745 |
| 11:36 ET | 1000 | 3.665 |
| 11:40 ET | 13874 | 3.67 |
| 11:44 ET | 100 | 3.68 |
| 11:47 ET | 9393 | 3.67 |
| 11:49 ET | 13471 | 3.7 |
| 11:51 ET | 4176 | 3.685 |
| 11:54 ET | 200 | 3.69 |
| 12:00 ET | 100 | 3.69 |
| 12:03 ET | 100 | 3.68 |
| 12:05 ET | 400 | 3.67 |
| 12:07 ET | 100 | 3.675 |
| 12:09 ET | 300 | 3.675 |
| 12:14 ET | 888 | 3.69 |
| 12:18 ET | 300 | 3.675 |
| 12:20 ET | 599 | 3.68 |
| 12:23 ET | 2500 | 3.675 |
| 12:30 ET | 15330 | 3.67 |
| 12:32 ET | 100 | 3.65 |
| 12:36 ET | 100 | 3.64 |
| 12:38 ET | 200 | 3.6348 |
| 12:39 ET | 400 | 3.64 |
| 12:41 ET | 11098 | 3.66 |
| 12:43 ET | 100 | 3.66 |
| 12:50 ET | 100 | 3.65 |
| 12:56 ET | 100 | 3.66 |
| 12:57 ET | 100 | 3.66 |
| 01:01 ET | 706 | 3.66 |
| 01:08 ET | 108 | 3.65 |
| 01:10 ET | 280 | 3.65 |
| 01:14 ET | 1200 | 3.65 |
| 01:15 ET | 819 | 3.645 |
| 01:17 ET | 100 | 3.645 |
| 01:21 ET | 587 | 3.64 |
| 01:24 ET | 443 | 3.632 |
| 01:26 ET | 400 | 3.6474 |
| 01:28 ET | 400 | 3.645 |
| 01:33 ET | 845 | 3.65 |
| 01:35 ET | 308 | 3.64 |
| 01:46 ET | 100 | 3.645 |
| 01:48 ET | 651 | 3.645 |
| 01:50 ET | 100 | 3.65 |
| 01:51 ET | 284 | 3.65 |
| 01:53 ET | 1726 | 3.64 |
| 01:55 ET | 500 | 3.64 |
| 01:57 ET | 1000 | 3.62 |
| 02:00 ET | 200 | 3.6201 |
| 02:06 ET | 1200 | 3.62 |
| 02:09 ET | 500 | 3.63 |
| 02:22 ET | 575 | 3.625 |
| 02:24 ET | 600 | 3.62 |
| 02:26 ET | 713 | 3.62 |
| 02:27 ET | 343 | 3.62 |
| 02:36 ET | 1783 | 3.61 |
| 02:38 ET | 100 | 3.61 |
| 02:40 ET | 100 | 3.615 |
| 02:42 ET | 200 | 3.615 |
| 02:45 ET | 100 | 3.615 |
| 02:49 ET | 105 | 3.615 |
| 02:58 ET | 357 | 3.615 |
| 03:00 ET | 1292 | 3.61 |
| 03:02 ET | 600 | 3.61 |
| 03:03 ET | 400 | 3.61 |
| 03:05 ET | 2200 | 3.615 |
| 03:07 ET | 127 | 3.61 |
| 03:09 ET | 100 | 3.61 |
| 03:14 ET | 200 | 3.605 |
| 03:18 ET | 3118 | 3.59 |
| 03:21 ET | 585 | 3.592 |
| 03:23 ET | 2287 | 3.59 |
| 03:30 ET | 1762 | 3.6 |
| 03:32 ET | 100 | 3.605 |
| 03:34 ET | 500 | 3.61 |
| 03:36 ET | 100 | 3.605 |
| 03:39 ET | 1190 | 3.62 |
| 03:41 ET | 418 | 3.605 |
| 03:43 ET | 619 | 3.605 |
| 03:45 ET | 1222 | 3.6 |
| 03:48 ET | 1340 | 3.6 |
| 03:50 ET | 1260 | 3.6 |
| 03:52 ET | 200 | 3.6 |
| 03:54 ET | 300 | 3.605 |
| 03:56 ET | 3286 | 3.595 |
| 03:57 ET | 923 | 3.595 |
| 03:59 ET | 1682 | 3.61 |
May 2, 2024
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform, from 4:30PM ET on Thursday May 02, 2024 by Dow Jones
4:30PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 199.6M | -0.7x | --- |
Galectin Therapeutics Inc | 201.2M | -4.1x | --- |
Boundless Bio Inc | 202.4M | -3.9x | --- |
Trevi Therapeutics Inc | 205.7M | -8.1x | --- |
Omeros Corp | 206.3M | -1.3x | --- |
Elevation Oncology Inc | 191.8M | -3.2x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Lead Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $199.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.47 |
EPS | $-4.97 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
